Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ischemic Preconditioning, Myocardial | 8 | 2005 | 23 | 0.910 |
Why?
|
| Myocardial Ischemia | 5 | 2007 | 117 | 0.880 |
Why?
|
| Myocardial Reperfusion Injury | 4 | 2007 | 29 | 0.740 |
Why?
|
| Myocardium | 5 | 2007 | 288 | 0.640 |
Why?
|
| Insecticides | 3 | 2006 | 45 | 0.620 |
Why?
|
| Protein Precursors | 2 | 2007 | 85 | 0.530 |
Why?
|
| Receptors, Opioid | 2 | 2007 | 15 | 0.460 |
Why?
|
| Diazepam | 2 | 2006 | 11 | 0.450 |
Why?
|
| Dichlorvos | 2 | 2006 | 15 | 0.440 |
Why?
|
| Rats | 13 | 2007 | 2005 | 0.400 |
Why?
|
| Diphenhydramine | 2 | 2003 | 9 | 0.390 |
Why?
|
| Histamine H1 Antagonists | 2 | 2003 | 10 | 0.390 |
Why?
|
| Fluorocarbons | 4 | 2002 | 44 | 0.380 |
Why?
|
| Jejunum | 2 | 2002 | 15 | 0.380 |
Why?
|
| Liquid Ventilation | 2 | 2002 | 4 | 0.360 |
Why?
|
| Rabbits | 8 | 2006 | 333 | 0.350 |
Why?
|
| Hypothermia, Induced | 2 | 2001 | 40 | 0.340 |
Why?
|
| Anti-Bacterial Agents | 4 | 2006 | 800 | 0.330 |
Why?
|
| Ischemia | 2 | 2002 | 196 | 0.330 |
Why?
|
| Pneumonia, Pneumococcal | 2 | 2002 | 28 | 0.320 |
Why?
|
| Animals | 27 | 2020 | 20962 | 0.310 |
Why?
|
| Management Quality Circles | 1 | 2009 | 2 | 0.310 |
Why?
|
| Organizational Case Studies | 1 | 2009 | 39 | 0.300 |
Why?
|
| Random Allocation | 6 | 2006 | 201 | 0.300 |
Why?
|
| Ursidae | 2 | 2020 | 12 | 0.300 |
Why?
|
| Enkephalin, Methionine | 2 | 2006 | 9 | 0.290 |
Why?
|
| Rats, Wistar | 8 | 2003 | 187 | 0.290 |
Why?
|
| Blood Transfusion | 2 | 1999 | 162 | 0.290 |
Why?
|
| Total Quality Management | 1 | 2008 | 56 | 0.280 |
Why?
|
| Enkephalins | 1 | 2007 | 20 | 0.270 |
Why?
|
| Opioid Peptides | 1 | 2007 | 4 | 0.270 |
Why?
|
| Efficiency, Organizational | 1 | 2008 | 96 | 0.270 |
Why?
|
| Naloxone | 3 | 2004 | 54 | 0.270 |
Why?
|
| Heart | 4 | 2007 | 288 | 0.270 |
Why?
|
| Physical Exertion | 1 | 2007 | 81 | 0.270 |
Why?
|
| Trauma Centers | 1 | 2008 | 127 | 0.270 |
Why?
|
| Glycopyrrolate | 2 | 2006 | 23 | 0.250 |
Why?
|
| Disease Models, Animal | 9 | 2007 | 2238 | 0.250 |
Why?
|
| Emergency Service, Hospital | 3 | 2013 | 1118 | 0.250 |
Why?
|
| Xylazine | 1 | 2006 | 4 | 0.250 |
Why?
|
| Cardiotonic Agents | 1 | 2006 | 54 | 0.240 |
Why?
|
| Antidotes | 1 | 2006 | 18 | 0.240 |
Why?
|
| Morphine | 1 | 2006 | 59 | 0.240 |
Why?
|
| Ketamine | 1 | 2006 | 38 | 0.230 |
Why?
|
| Hypothermia | 2 | 2001 | 17 | 0.210 |
Why?
|
| Carotid Arteries | 2 | 2001 | 61 | 0.210 |
Why?
|
| Narcotics | 1 | 2004 | 57 | 0.210 |
Why?
|
| Apnea | 1 | 2004 | 32 | 0.210 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 783 | 0.210 |
Why?
|
| Muscle Relaxants, Central | 1 | 2003 | 12 | 0.210 |
Why?
|
| Tobramycin | 1 | 2003 | 7 | 0.210 |
Why?
|
| Organophosphorus Compounds | 1 | 2003 | 32 | 0.210 |
Why?
|
| In Vitro Techniques | 5 | 2002 | 490 | 0.200 |
Why?
|
| Klebsiella Infections | 1 | 2003 | 22 | 0.200 |
Why?
|
| Hibernation | 2 | 2020 | 10 | 0.200 |
Why?
|
| Neutron Activation Analysis | 1 | 2003 | 3 | 0.200 |
Why?
|
| Ventricular Fibrillation | 2 | 2001 | 107 | 0.200 |
Why?
|
| Iohexol | 1 | 2003 | 18 | 0.200 |
Why?
|
| Muscarinic Antagonists | 1 | 2003 | 33 | 0.190 |
Why?
|
| Organophosphate Poisoning | 1 | 2002 | 14 | 0.190 |
Why?
|
| Pneumonia, Bacterial | 1 | 2003 | 89 | 0.190 |
Why?
|
| Central Nervous System Diseases | 1 | 2003 | 58 | 0.190 |
Why?
|
| Enkephalin, Leucine-2-Alanine | 1 | 2002 | 2 | 0.190 |
Why?
|
| Receptors, Opioid, delta | 1 | 2002 | 5 | 0.190 |
Why?
|
| Potassium Channels | 1 | 2002 | 58 | 0.180 |
Why?
|
| Vaccines | 1 | 2023 | 98 | 0.180 |
Why?
|
| Swine | 4 | 2007 | 395 | 0.180 |
Why?
|
| Arm Injuries | 1 | 2001 | 12 | 0.180 |
Why?
|
| Leg Injuries | 1 | 2001 | 16 | 0.180 |
Why?
|
| Reperfusion Injury | 1 | 2002 | 56 | 0.180 |
Why?
|
| Myocardial Reperfusion | 4 | 2006 | 24 | 0.180 |
Why?
|
| Respiratory Insufficiency | 1 | 2003 | 154 | 0.180 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2007 | 625 | 0.180 |
Why?
|
| Ventricular Function, Left | 2 | 2000 | 271 | 0.170 |
Why?
|
| Rewarming | 1 | 2001 | 6 | 0.170 |
Why?
|
| Resuscitation | 1 | 2001 | 74 | 0.170 |
Why?
|
| Patient Discharge | 1 | 2024 | 507 | 0.160 |
Why?
|
| Hemostasis | 1 | 2020 | 18 | 0.160 |
Why?
|
| Coronary Vessels | 2 | 2009 | 124 | 0.160 |
Why?
|
| Pharmaceutical Services | 1 | 2020 | 33 | 0.160 |
Why?
|
| Pain Measurement | 1 | 2001 | 349 | 0.160 |
Why?
|
| Drug Costs | 1 | 2020 | 57 | 0.160 |
Why?
|
| Femoral Artery | 1 | 2001 | 99 | 0.160 |
Why?
|
| Patient Readmission | 1 | 2024 | 432 | 0.160 |
Why?
|
| RNA, Viral | 1 | 2021 | 275 | 0.160 |
Why?
|
| Ischemic Preconditioning | 1 | 1999 | 8 | 0.160 |
Why?
|
| Norepinephrine | 1 | 1999 | 103 | 0.150 |
Why?
|
| Adenosine | 1 | 1999 | 78 | 0.150 |
Why?
|
| Narcotic Antagonists | 3 | 2007 | 132 | 0.150 |
Why?
|
| Drug Utilization | 1 | 2020 | 208 | 0.150 |
Why?
|
| Accountable Care Organizations | 1 | 2020 | 67 | 0.150 |
Why?
|
| Myocardial Infarction | 3 | 2001 | 915 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 869 | 0.150 |
Why?
|
| Pain | 1 | 2001 | 407 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 147 | 0.150 |
Why?
|
| Male | 17 | 2024 | 30323 | 0.140 |
Why?
|
| Blood Coagulation | 1 | 2017 | 39 | 0.130 |
Why?
|
| Respiration, Artificial | 2 | 1999 | 296 | 0.120 |
Why?
|
| Hemodynamics | 3 | 2001 | 249 | 0.120 |
Why?
|
| Prospective Studies | 4 | 2003 | 3318 | 0.120 |
Why?
|
| Patient Satisfaction | 2 | 2009 | 439 | 0.120 |
Why?
|
| Sensitivity and Specificity | 3 | 2003 | 1164 | 0.110 |
Why?
|
| Muscle, Smooth | 2 | 2007 | 134 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2020 | 697 | 0.100 |
Why?
|
| Humans | 16 | 2024 | 64279 | 0.100 |
Why?
|
| Brain | 2 | 2003 | 1581 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2007 | 1551 | 0.090 |
Why?
|
| Perfusion | 3 | 2000 | 72 | 0.090 |
Why?
|
| Body Temperature | 2 | 2001 | 45 | 0.090 |
Why?
|
| Muscle Contraction | 2 | 2002 | 202 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2001 | 608 | 0.080 |
Why?
|
| Connective Tissue | 1 | 2009 | 12 | 0.070 |
Why?
|
| Time Factors | 3 | 2009 | 3726 | 0.070 |
Why?
|
| Vascular Surgical Procedures | 2 | 2001 | 244 | 0.070 |
Why?
|
| Hospitals, Community | 1 | 2009 | 71 | 0.070 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 106 | 0.070 |
Why?
|
| Midwestern United States | 1 | 2008 | 25 | 0.070 |
Why?
|
| Organizational Innovation | 1 | 2009 | 82 | 0.070 |
Why?
|
| Intra-Abdominal Fat | 1 | 2009 | 35 | 0.070 |
Why?
|
| Hospitals, Rural | 1 | 2008 | 19 | 0.070 |
Why?
|
| Seasons | 2 | 2020 | 138 | 0.070 |
Why?
|
| Subcutaneous Fat | 1 | 2009 | 47 | 0.070 |
Why?
|
| Health Plan Implementation | 1 | 2008 | 40 | 0.070 |
Why?
|
| Poisoning | 2 | 2006 | 31 | 0.070 |
Why?
|
| Adipogenesis | 1 | 2009 | 79 | 0.070 |
Why?
|
| Dietary Fats | 1 | 2009 | 175 | 0.070 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 178 | 0.070 |
Why?
|
| Epithelium | 1 | 2007 | 96 | 0.070 |
Why?
|
| Kidney | 2 | 2007 | 455 | 0.070 |
Why?
|
| Pandemics | 2 | 2023 | 676 | 0.070 |
Why?
|
| Models, Animal | 2 | 2009 | 240 | 0.070 |
Why?
|
| Aging | 2 | 2005 | 754 | 0.070 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 239 | 0.060 |
Why?
|
| Naltrexone | 1 | 2007 | 88 | 0.060 |
Why?
|
| United States | 4 | 2021 | 7923 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 458 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 544 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2007 | 614 | 0.060 |
Why?
|
| Adipocytes | 1 | 2009 | 269 | 0.060 |
Why?
|
| Intestines | 1 | 2007 | 169 | 0.060 |
Why?
|
| Injections, Intramuscular | 1 | 2006 | 72 | 0.060 |
Why?
|
| Hospitalization | 1 | 2013 | 1368 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 5528 | 0.060 |
Why?
|
| Cystitis | 1 | 2005 | 10 | 0.060 |
Why?
|
| Staphylococcus | 1 | 2005 | 17 | 0.060 |
Why?
|
| Reference Values | 1 | 2006 | 333 | 0.060 |
Why?
|
| Intestinal Mucosa | 1 | 2007 | 243 | 0.060 |
Why?
|
| Gram-Negative Bacteria | 1 | 2005 | 56 | 0.060 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2005 | 41 | 0.060 |
Why?
|
| Length of Stay | 1 | 2009 | 819 | 0.060 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2006 | 58 | 0.060 |
Why?
|
| Massachusetts | 2 | 2021 | 2096 | 0.060 |
Why?
|
| Female | 7 | 2024 | 33382 | 0.060 |
Why?
|
| Urinary Tract Infections | 1 | 2006 | 93 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2020 | 2605 | 0.060 |
Why?
|
| Drug Resistance | 1 | 2005 | 155 | 0.050 |
Why?
|
| Aged | 4 | 2024 | 14664 | 0.050 |
Why?
|
| Middle Aged | 4 | 2020 | 17923 | 0.050 |
Why?
|
| Inflammation | 2 | 2009 | 1162 | 0.050 |
Why?
|
| Gene Expression | 1 | 2007 | 851 | 0.050 |
Why?
|
| Allied Health Personnel | 1 | 2024 | 29 | 0.050 |
Why?
|
| Transitional Care | 1 | 2024 | 27 | 0.050 |
Why?
|
| Intubation | 1 | 2003 | 11 | 0.050 |
Why?
|
| Mass Vaccination | 1 | 2023 | 10 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2009 | 3450 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2024 | 107 | 0.050 |
Why?
|
| Ventilators, Mechanical | 1 | 2003 | 30 | 0.050 |
Why?
|
| Klebsiella pneumoniae | 1 | 2003 | 30 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2003 | 55 | 0.050 |
Why?
|
| Ipratropium | 1 | 2003 | 7 | 0.050 |
Why?
|
| Xenon Isotopes | 1 | 2003 | 3 | 0.050 |
Why?
|
| Cholinergic Antagonists | 1 | 2003 | 32 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2003 | 58 | 0.050 |
Why?
|
| Iodine | 1 | 2003 | 20 | 0.050 |
Why?
|
| Glyburide | 1 | 2002 | 9 | 0.050 |
Why?
|
| Tissue Extracts | 1 | 2002 | 11 | 0.050 |
Why?
|
| Potassium Channel Blockers | 1 | 2002 | 27 | 0.050 |
Why?
|
| Mesentery | 1 | 2002 | 17 | 0.050 |
Why?
|
| Splanchnic Circulation | 1 | 2002 | 16 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 747 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2003 | 120 | 0.050 |
Why?
|
| Hydrocarbons, Brominated | 1 | 2002 | 4 | 0.050 |
Why?
|
| Apoptosis | 1 | 2007 | 1094 | 0.050 |
Why?
|
| Infusions, Parenteral | 1 | 2002 | 22 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2024 | 577 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2002 | 230 | 0.050 |
Why?
|
| Enkephalin, Leucine | 1 | 2001 | 7 | 0.040 |
Why?
|
| Radioimmunoassay | 1 | 2001 | 63 | 0.040 |
Why?
|
| Epinephrine | 1 | 2001 | 47 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 215 | 0.040 |
Why?
|
| Hypoxia | 1 | 2002 | 116 | 0.040 |
Why?
|
| Phenylpropanolamine | 1 | 2001 | 1 | 0.040 |
Why?
|
| Phentolamine | 1 | 2001 | 7 | 0.040 |
Why?
|
| Therapeutic Irrigation | 1 | 2001 | 17 | 0.040 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2001 | 21 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 375 | 0.040 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2001 | 16 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2006 | 718 | 0.040 |
Why?
|
| Vaccination | 1 | 2023 | 371 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 1020 | 0.040 |
Why?
|
| Antithrombin III | 1 | 2020 | 14 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2020 | 56 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2001 | 199 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2002 | 587 | 0.040 |
Why?
|
| Ventricular Pressure | 1 | 2000 | 31 | 0.040 |
Why?
|
| Body Weight | 1 | 2001 | 379 | 0.040 |
Why?
|
| Heart Rate | 1 | 2001 | 328 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 1999 | 53 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 375 | 0.040 |
Why?
|
| Glucose | 1 | 2002 | 471 | 0.040 |
Why?
|
| Kerosene | 1 | 1999 | 1 | 0.040 |
Why?
|
| Models, Cardiovascular | 1 | 1999 | 79 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2001 | 177 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2001 | 517 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2001 | 265 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2020 | 220 | 0.040 |
Why?
|
| Penicillin G | 1 | 1998 | 5 | 0.030 |
Why?
|
| Adolescent | 3 | 2006 | 6305 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2020 | 405 | 0.030 |
Why?
|
| Brain Ischemia | 1 | 2001 | 421 | 0.030 |
Why?
|
| Mice | 2 | 2009 | 11003 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1570 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2001 | 1561 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 1494 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2006 | 5697 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2020 | 6742 | 0.030 |
Why?
|
| Rats, Inbred F344 | 2 | 2005 | 56 | 0.020 |
Why?
|
| Triage | 1 | 2013 | 128 | 0.020 |
Why?
|
| Patient Admission | 1 | 2013 | 198 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2006 | 1375 | 0.020 |
Why?
|
| Adult | 2 | 2013 | 17133 | 0.020 |
Why?
|
| Infant | 2 | 2006 | 1664 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 1105 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2006 | 2019 | 0.020 |
Why?
|
| Cell Shape | 1 | 2009 | 12 | 0.020 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2009 | 14 | 0.020 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2009 | 22 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2009 | 57 | 0.020 |
Why?
|
| Adiponectin | 1 | 2009 | 37 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2009 | 92 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2009 | 77 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2009 | 77 | 0.020 |
Why?
|
| Adipose Tissue, Brown | 1 | 2009 | 119 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 325 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2009 | 156 | 0.020 |
Why?
|
| Child | 2 | 2006 | 4583 | 0.010 |
Why?
|
| Okadaic Acid | 1 | 2005 | 9 | 0.010 |
Why?
|
| Protein Phosphatase 2 | 1 | 2005 | 12 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 1222 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2009 | 2177 | 0.010 |
Why?
|
| Cell Death | 1 | 2005 | 286 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 672 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 373 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2005 | 317 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2005 | 948 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 1621 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2001 | 47 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2000 | 89 | 0.010 |
Why?
|
| Longevity | 1 | 2001 | 116 | 0.010 |
Why?
|
| Necrosis | 1 | 2000 | 146 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 1999 | 158 | 0.010 |
Why?
|
| Intubation, Intratracheal | 1 | 1999 | 203 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2005 | 3070 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1999 | 1683 | 0.010 |
Why?
|